CMSS1 anticorps (AbBy Fluor® 647)
-
- Antigène Voir toutes CMSS1 Anticorps
- CMSS1 (Cms Small Ribosomal Subunit 1 (CMSS1))
-
Reactivité
- Humain, Souris, Rat
-
Hôte
- Lapin
-
Clonalité
- Polyclonal
-
Conjugué
- Cet anticorp CMSS1 est conjugé à/à la AbBy Fluor® 647
-
Application
- Western Blotting (WB)
- Réactivité croisée
- Humain
- Homologie
- Mouse,Rat,Horse
- Purification
- Purified by Protein A.
- Immunogène
- KLH conjugated synthetic peptide derived from human C3orf26
- Isotype
- IgG
- Top Product
- Discover our top product CMSS1 Anticorps primaire
-
-
- Indications d'application
- IF(IHC-P) 1:50-200
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Concentration
- 1 μg/μL
- Buffer
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
- Agent conservateur
- Sodium azide
- Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
- Stock
- -20 °C
- Stockage commentaire
- Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
- Date de péremption
- 12 months
-
- Antigène
- CMSS1 (Cms Small Ribosomal Subunit 1 (CMSS1))
- Autre désignation
- C3orf26 (CMSS1 Produits)
- Sujet
-
Synonyms: C3orf26, CC026_HUMAN, MGC4308, Uncharacterized protein C3orf26.
Background: Chromosome 3 is made up of about 214 million bases encoding over 1,100 genes. Notably, there is a chemokine receptor gene cluster and a variety of human cancer related loci on chromosome 3. Particular regions of the chromosome 3 short arm are deleted in many types of cancer cells. Key tumor suppressing genes on chromosome 3 encode apoptosis mediator RASSF1, cell migration regulator HYAL1 and angiogenesis suppressor SEMA3B. Marfan Syndrome, porphyria, von Hippel-Lindau syndrome, osteogenesis imperfecta and Charcot-Marie-Tooth Disease are a few of the numerous genetic diseases associated with chromosome 3. The C3orf26 gene product has been provisionally designated C3orf26 pending further characterization.
-